公开(公告)号：US20200237927A1

公开(公告)日：2020-07-30

申请号：US16786158

申请日：2020-02-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Emma Masteller ,  Thomas Brennan ,  David Bellovin ,  Kevin Baker ,  Brian Wong

IPC: A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

公开(公告)号：US20180085472A1

公开(公告)日：2018-03-29

申请号：US15564866

申请日：2016-04-12

Applicant: Five Prime Therapeutics, Inc.

Inventor： Emma Masteller ,  Thomas Brennan ,  David Bellovin ,  Kevin Baker ,  Brian Wong

IPC: A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61P35/00

CPC classification number: A61K47/6879 ,  A61K47/6851 ,  A61K51/1084 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2866 ,  C07K16/2878

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

公开(公告)号：US20170145071A1

公开(公告)日：2017-05-25

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K45/06

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US11559583B2

公开(公告)日：2023-01-24

申请号：US16786158

申请日：2020-02-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Emma Masteller ,  Thomas Brennan ,  David Bellovin ,  Kevin P. Baker ,  Brian Wong

IPC: C07K16/28 ,  A61P35/00 ,  A61K51/10 ,  A61K39/00 ,  A61K47/68

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

公开(公告)号：US10273281B2

公开(公告)日：2019-04-30

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K16/00 ,  C07K16/28 ,  A61K38/00

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US20180016555A1

公开(公告)日：2018-01-18

申请号：US15520998

申请日：2015-10-21

Applicant: Five Prime Therapeutics, Inc.

Inventor： Luis Borges ,  Nathan Sallee ,  Charles Kaplan ,  Arthur Brace ,  W. Michael Kavanaugh ,  Brian Wong ,  David Bellovin ,  Thomas Brennan ,  Artur Karasyov

IPC: C12N5/0783 ,  C07K16/28 ,  G01N33/50

CPC classification number: C12N5/0636 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/76 ,  C07K2319/30 ,  C12N2501/599 ,  G01N33/505

Abstract: Methods of identifying and using SLAMF1 antagonists are provided.

公开(公告)号：US11789010B2

公开(公告)日：2023-10-17

申请号：US16608911

申请日：2018-04-27

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  Barbara Sennino ,  Susannah D. Barbee ,  Ursula Jeffry

IPC: G01N33/50 ,  G01N15/10 ,  G01N15/00

CPC classification number: G01N33/5011 ,  G01N15/10 ,  G01N2015/0065 ,  G01N2015/1006 ,  G01N2333/70532 ,  G01N2800/52

Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.

公开(公告)号：US20220168416A1

公开(公告)日：2022-06-02

申请号：US17554423

申请日：2021-12-17

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Kristen Pierce ,  Namrata Patil ,  Thomas Brennan ,  Julie Hambleton

IPC: A61K39/395 ,  C07K16/28 ,  A61K33/243 ,  A61K31/337 ,  A61K31/513 ,  A61K45/06

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

公开(公告)号：US20160106809A1

公开(公告)日：2016-04-21

申请号：US14890047

申请日：2014-05-22

Applicant: FIVE PRIME THERAPEUTICS, INC. ,  GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

Inventor： David Bellovin ,  Kevin Baker ,  Thomas Brennan ,  Arundathy Nirmalini Pandite ,  Bijoyesh Mookerjee ,  Maurice P. DeYoung ,  Rakesh Kumar

IPC: A61K38/17 ,  A61K33/24 ,  A61K31/337 ,  G01N33/574 ,  A61K31/519 ,  C07K14/71 ,  C12Q1/68 ,  A61K45/06 ,  A61K31/555

CPC classification number: A61K38/179 ,  A61K31/337 ,  A61K31/519 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57496 ,  G01N2333/49 ,  G01N2333/50 ,  G01N2333/503 ,  G01N2333/515 ,  G01N2800/52

Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.

Abstract translation: 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子的癌症治疗方法。 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子和至少一种抗血管生成剂的治疗癌症的方法。

公开(公告)号：US20150203566A1

公开(公告)日：2015-07-23

申请号：US14577330

申请日：2014-12-19

Applicant: Five Prime Therapeutics, Inc.

Inventor： Li Long ,  Thomas Brennan

IPC: C07K14/71 ,  A61K31/337 ,  A61K33/24 ,  A61K31/365 ,  A61K31/513 ,  A61K31/282 ,  A61K39/395 ,  A61K31/704 ,  A61K38/17 ,  A61K31/519

CPC classification number: C07K14/71 ,  A61K31/282 ,  A61K31/337 ,  A61K31/365 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24 ,  A61K38/179 ,  A61K38/38 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/507 ,  C07K2319/30 ,  A61K2300/00

Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

Abstract translation: 治疗癌症的方法包括与选自多西紫杉醇，紫杉醇，长春新碱，卡铂，顺铂，奥沙利铂的至少一种另外的治疗剂组合施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子 ，多柔比星，5-氟尿嘧啶（5-FU），亚叶酸，培美曲塞和贝伐珠单抗。 包含FGFR1 ECD和/或FGFR1 ECD融合分子和/或选自多西紫杉醇，紫杉醇，长春新碱，卡铂，顺铂，奥沙利铂，多柔比星，5-氟尿嘧啶（5-FU），亚叶酸， 还提供了培美曲塞和贝伐珠单抗。 在一些实施方案中，剂量包含有用至少一种另外的治疗剂施用FGFR1 ECD和/或FGFR1 ECD融合分子的说明书。